Investor Relations

Corporate Overview

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. With fiscal year 2011 revenue of over $400 million and more than 1,100 employees, Myriad is working on strategic directives, including new test introductions, companion diagnostics, and international expansion to take advantage of significant growth opportunities that further the Company’s mission. Our employees are a talented, dedicated, diverse group of individuals united in a common goal of making a difference by improving the quality of patient’s lives and saving lives.

News Releases

May 16, 2012
Myriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting

May 9, 2012
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0

View all releases »

Events & Presentations

Myriad Corporate Presentation

Upcoming Event
May 16, 2012 4:20 PM PT	Bank of America Merrill Lynch 2012 Health Care Conference Speaker: Peter D. Meldrum, President and CEO Listen to webcast

View all events & presentations »